The poliovirus receptor PVR, also known as CD155 or NECL-5. PVR mediates natural killer cell adhesion and triggers its effector function, participates in mediating tumor cell infiltration and migration, and is the attachment receptor of poliovirus. PVR is expressed in monocytes, macrophages, thymocytes and neurons of the central nervous system. PVR is able to bind CD226, DNAX accessory molecule-1 (DNAM-1), T Cell-Activated Increased Late Expression Protein, TACTILE (CD96), and T Cell Immunoreceptor with Ig and ITIM domains (TIGIT). PVR expression was associated with an unfavorable prognosis in solid tumors such as colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma. Nectin Therapeutics is developing a CD155 antibody, NTX-1088, in clinical phase. Raji-OS8 stable cell was used as an artificial antigen presenting cells (APCs), OS8 could function as a membrane anchored T cell engager that directly activates TCR in T cell-based assay.